Using BlueSkeye artificial intelligence program to diagnose depression in pregnant women

BlueSkeye recently announced that it is designing a program that detects possible depression by scanning the faces and voices of pregnant women at different stages of this sensitive period. It also analyzes various aspects of this disease in these women.

The Medical and Health Products Regulatory Agency (MHRA) plans to create a program with the help of artificial intelligence that can identify and determine the dimensions of women's depression at different stages of pregnancy. In a clinical trial that is going to be conducted on 125 pregnant women from early 2024, the level of safety and efficiency of this program will be determined. The trial will be carried out in NHS hospitals in partnership with the British Institute of Mental Health and will last for 14 months.

In BlueSkeye's artificial intelligence program, AI scans the user's face and analyzes his voice to monitor his depression symptoms. The purpose of this trial is to determine to what extent such a program can be used in real life and how well it meets standard clinical criteria for depression.

Professor Michael Wallstar, CEO of BlueSkeye AI, says:

“A total of one in five women is struggling with symptoms of depression during pregnancy. Some of these people take necessary measures for treatment; While many of them do not have access to the necessary care. NHS hospitals in the UK are costing £1.2 billion a year if they don't get the treatment they need in time.”

To ensure the safety of this program, 12 participants are studied in the first stage. Another 113 people sign up just to get more information. Patients in this trial talk to the program once a week. This program monitors the patients' faces and voices throughout the conversation and compares their depression symptoms with the data it has from their health questionnaires.

The use of health applications facilitates remote monitoring of disease symptoms. BlueSkeye's artificial intelligence program, which collects data from users' facial expressions and voice, will be useful for people who cannot access support. It is interesting to know that the giants of the technology industry, such as Apple, have each launched their own mental health tracking platforms.

In addition, to increase cyber security and prevent disclosure of personal data stored in applications, BlueSkeye's official artificial intelligence website encrypts users' personal information using algorithms. It has also announced that these encryptions are fully compliant with GDPR standards.

The Medicines and Healthcare Products Regulatory Agency (MHRA), in collaboration with artificial intelligence company BlueSkey, is launching an app that can detect symptoms of depression at different stages of pregnancy. From the beginning of 2024, the safety and efficiency of this application will be determined in a clinical trial conducted on 125 women. It should be noted that the security of this program is sufficiently ensured by the specialized encryption of user data.